France
Inovotion is a biotech company founded in 2014 in France and has been making significant strides in the areas of biotechnology, healthcare, pharmaceuticals, and robotics. The company specializes in offering a unique in vivo technology dedicated to anti-cancer treatment evaluations and early toxicity studies.
Their technology, which is based on chick embryo, provides early analysis of treatments before the classical preclinical stages, thereby eliminating low-value molecules early and accelerating the drug discovery process. This approach not only saves time and money but also provides a clear competitive advantage. The company's core focus is on providing efficacy assays for anti-cancer treatments, early toxicity assays for drug candidates, target validation in oncology, and multi-cancer screening to (re)position treatments.
Their innovative approach assists chemists and biologists from companies and universities to validate a target and develop treatments within their budget. The last investment of €50.00K was received as a grant investment on 01 January 2017 from EASME - EU Executive Agency for SMEs.
Inovotion's accessible efficacy and toxicity assays open new perspectives for a wide variety of project researches with rapid Go/No Go decisions. The company's slogan "Which molecule will stand out" resonates with its commitment to helping clients focus their R&D on high-value molecules. In conclusion, Inovotion's groundbreaking technology and strategic approach not only hold promise for the company itself but also for the future of cancer treatment and drug development.
